New updates in the world of hepatitis C virus infected organ transplantation. Issue 4 (August 2020)

• Record Type: Journal Article
• Authors: Prakash, Katya; Aslam, Saima
• Is Part Of: Current opinion in organ transplantation. Volume 25:Issue 4(2020:Aug.)
• Publication Date: 2020-08
• Subjects: hepatitis C -- solid organ transplantation -- treatment; Transplantation of organs, tissues, etc -- Periodicals; Immunosuppression -- Periodicals; Transplantation immunology -- Periodicals; 617.954
• DOI: 10.1097/MOT.0000000000000785
• Languages: English
• ISSNs: 1087-2418

Abstract

Abstract : Purpose of review: With the advent of direct acting antiviral (DAA) therapy, the use of organs from hepatitis C virus infected (HCV+) donors is gaining more traction. In this review, we aim to: provide an overview of recent literature that supports the use of HCV+ organs, outline ongoing challenges to the use of these organs, and highlight the areas within this field where active investigation is ongoing. Recent findings: The present review describes clinical outcomes related to the transplantation of both HCV+ nonviremic and viremic organs and the distinction between hepatic and nonhepatic transplants. It also discusses the current debate pertaining to the ideal treatment strategy for donor-derived HCV infection, that is pre-emptive therapy versus prophylaxis therapy. Summary: Data suggest that the use of HCV+ organs is an effective and relatively well tolerated strategy to combat the organ scarcity. However, clinicians must be vigilant to a signal of increased inflammation as HCV+ organ transplantation becomes more universal. Recent studies suggest that shorter courses of DAA may sufficiently treat donor-derived HCV infection, however the best treatment approach to minimize risk, cost, and toxicity is still under investigation.